MP2PRT: Identification of Genetic Changes Associated with Relapse and/or Adaptive Resistance in Patients Registered as Favorable Histology Wilms Tumor on AREN03B2

The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI's Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program. This study, titled "Identification of Genetic Changes Associated with Relapse and/or Adaptive Resistance in Patients Registered as Favorable Histology Wilms Tumor on AREN03B2", performs genomic characterization (WGS 30X, Total RNAseq, miRNAseq) on a discovery set of 70 trio cases (normal tissue, tumor tissue at time of diagnosis, tumor tissue at time of relapse) from patients who relapsed with Favorable Histology Wilms Tumor. Prioritized findings from the discovery set will be validated using Targeted Sequencing in an independent validation set of 47 relapse samples.]]>
The inclusion criteria for eligibility include all of the following: Registered on AREN03B2 as favorable histology Wilms tumor (FHWT) of any stage and relapse following therapy with FHWT. Patients who developed contralateral disease were not considered to have relapsed for this study; patients with bilateral disease were only considered as relapse if a clearly identifiable tumor clearly progressed while on therapy. Have a valid consent. Received Vincristine and Actinomycin within their chemotherapy regimen following diagnosis. Patients who relapsed after surveillance alone were not included. Have banked samples at the Children's Oncology Group Biopathology Center of sufficient size from relapse sample. For the discovery set, appropriate samples from a source of germline DNA must also be available. ]]>